Patient Identification Number for this trial:

HOME PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT FORM

Treatment for patients with confirmed COVID-19

A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

We would like to invite you to take part in a research study. Before you decide whether to take part, it is important for you to understand why the research is being done and what it would involve for you. One of our team will go through the information sheet with you and answer any questions you may have. Please take time to read the following information carefully. We anticipate that this will take about 30 minutes to read. Talk to others about the study if you wish.

The information sheet is in two parts. Part A tells you the purpose of this study and what will happen to you if you take part. Part B gives you more detailed information about the conduct of the study.

Thank you for reading this.

PART A

What is the purpose of this study?
The purpose of this research study is to test SNG001 (the study medication). SNG001 is an inhaled drug that contains interferon-β, an antiviral protein that occurs naturally in the body. Interferon-β has been given as an injection to thousands of patients for other diseases (such as multiple sclerosis), this trial is about giving SNG001 by inhalation. By administering SNG001 as an aerosol through a nebuliser directly to the lungs it is hoped that the interferon-β can boost the lungs’ antiviral defences and reduce the severity of illness caused by viruses. Recent research has suggested that Interferon-β, if given by inhalation might protect the cells in the lungs from cold and flu viruses in vulnerable patients e.g. patient in hospital and those of advanced age and people with some chronic illnesses.

SARS-CoV-2 infection is a new type of coronavirus that appeared in China in 2019 that causes COVID-19, an acute lung disease. There are currently no drug treatments proven to help patients who have COVID-19. Due
to the nature of the disease and how easily it is spread, it is a global threat and there is a need to assess new treatments which could prevent and effectively treat COVID-19.

It is possible that SNG001 could be given as a treatment to patients with confirmed COVID-19 in order to prevent/limit the worsening of lower respiratory tract illness. We first need to test the study medication to see if it can ‘switch on’ the antiviral defences in the lungs in a way which would help them to fight viruses. The study medication would be given in addition to the normal medical care that patients should receive.

The design of the study is double-blind, randomised and placebo controlled. A double-blind study means that neither you or the study doctor will know whether you receive SNG001 or placebo (a ‘dummy treatment’, which looks like the study medicine but does not contain the active ingredient, Interferon-β). Placebo is needed in clinical trials to help researchers work out whether a new medicine is beneficial or not. Just being in a trial and taking a study medication can make people feel better. Having placebo in the trial means that the drug effects can be distinguished from any effects of simply being in the trial and taking a trial medication. In the case of an emergency, the trial can be unblinded for a patient to see if they are receiving SNG001 or placebo.

To be randomised means allocation to receive either SNG001 or placebo will be by chance. For this study you are equally likely to receive SNG001 as to receive placebo.

**Why have I been invited?**

You have been invited to take part in this study because you have suspected COVID-19 and are considered to be more susceptible to complications of your lung infection, based on your age and/or other illnesses you may have.

**Do I have to take part?**

It is up to you to decide; participation in the study is entirely voluntary. If you do decide to take part, you are still free to withdraw at any time, without giving a reason, and without your standard medical care being affected.

**What will happen to me if I take part?**

Between 100 and 600 patients with confirmed COVID-19 will be enrolled into this study.

If, after reading this information sheet, you are interested in taking part in the study, please contact the study team via the study website at [www.covidtrialathome.com](http://www.covidtrialathome.com). A doctor will then get in contact with you to discuss the study in detail and you will be given the opportunity to ask any questions. After this discussion, if you are happy, your consent to take part in the trial will be taken either via an electronic system or verbally. No tests will be performed until after you have confirmed your consent.
Once you have given your consent, the study doctor will run through the eligibility questions with you. If the initial eligibility questions indicate that you are suitable for the trial and you have not had a swab test already, a test kit will be sent out to you to see if you have COVID-19. This will involve you taking a swab from your nose or throat (study doctor or nurse will guide you through this). If the test confirms that you have COVID-19 and are eligible for the trial, a pack containing the trial medication will be sent out to you by express courier. A healthcare professional will, via video call, answer any questions you might have and help you record your temperature and oxygen saturation (we will provide you with devices to do this), and take your trial medication. This guidance via video call will take place each day that you take the trial medication.

You will be asked to take a dose of the study medication once a day for 14 days. A number of tests (such as checking your pulse and temperature) and questionnaires will be conducted throughout to assess the effects of the study medication.

You will see a doctor via video call on Day 1 and a healthcare professional via video call for Days 2-14 of the trial. Once you have finished taking the study medication you will receive four further follow-up calls from healthcare professional in the study team (These calls with be at Day 60 and 90 after treatment. There will be a window of +/- 3 days on these video calls so that the study team can fit around your availability). Day 90 visits should be completed within the +/- 3 day window wherever possible. If the Day 90 is outside this window, the visit can still be conducted up to + 365 days but we will try to complete this visit with you as soon as possible.

The following will be carried out at different times when you see study staff:

- **Medical history** - the doctor will ask you a number of questions about your health problems.
- **COVID-19 history** – the doctor will ask you a number of questions about the coronavirus infection you currently have.
- **Demographics** – you will be asked your age, date of birth, sex and race.
- **Questionnaires** – there will be a number of questions that either the doctor or study staff will ask you. These will be about your current health status and how you are feeling. This will include questions at day 60 and day 90 about longer lasting symptoms of COVID-19 that you may be experiencing, these questionnaires will be focusing on:
  - General Anxiety
  - Health Questionnaire
  - Fatigue
  - Every-day activities
• **Vital signs** – Within the pack you are provided, alongside your study treatment, you will be given a thermometer and pulse oximeter. Under the guidance of a study healthcare professional, you will be asked to take your temperature, pulse and measure the oxygen levels in your blood using a small device that clips onto your finger.

If for any reason you cannot be included in the study, the healthcare professional will assist you to ensure you receive the correct standard care.

Below is a list of all study visits and the assessments that will be carried out at each visit.

**Day 1 (approximately 2 hours)**
This visit determines whether you are eligible to participate in the study. These assessments will be completed over video call with a trained doctor.

The following will take place prior to confirmation of eligibility:

- Discuss the study and give your consent to take part in the study
- Medical history (including the viral infection history)
- Demographics and a review of any medication you are taking
- Nasal or throat swab to test for coronavirus infection (if required) or the study doctor/nurse has seen confirmation of positive result from another swab you have had taken

If you have not had a swab test already, the swab will then be sent by courier to a local laboratory, where it will be tested for coronavirus. If coronavirus infection is not confirmed, then you will not be able to join the trial. You will need to contact normal NHS services if you have any medical needs.

If your coronavirus infection is confirmed, you will be informed and arrangements will be made for the study medication and equipment to be sent to you. Once this has arrived (on the same day or one day after your initial assessment), the following assessments will be carried out with a healthcare professional over video call:

- Respiratory assessment and other questionnaires
- Vital signs (including temperature, heart rate, and oxygen saturations)
- Training on the inhalation device, in preparation for the first dose of study medication
- Dose administration
Days 2 to 14 (all 1 hour)

The following assessments will be conducted via video call:

- Respiratory assessment and other questionnaires
- Vital signs (including temperature, pulse and oxygen saturation)
- Instruction to administer the daily dose of study medication
- Dose administration

End of treatment (1 or 2 days after your last dose of study medication, 1 hour)

The following assessments will be conducted via video call:

- Respiratory assessment and other questionnaires
- Vital signs (including temperature, pulse, oxygen saturation, height and weight)

Follow up video calls (day 60 and day 90, all 1 hour)

The following assessments will be conducted via video call:

- Respiratory assessment.
- Questionnaires will be completed including general anxiety, health questionnaire, fatigue and every-day activities.

Additional Assessments

It may also be necessary to have additional repeat assessments performed either during the study or after you have finished the study. The study doctor will decide if this is necessary.

If you are not recruited by your own GP, they will be notified of your participation in this study if you give consent for this to be done.

Expenses and payments

There will be no reimbursement for taking part in this study.

What will I have to do?

You will be expected to:

- Complete the study assessments when required.
- Continue taking your usual medications
During the study you should report to the study doctor or nurse any changes to your health, including any illnesses or symptoms that you experience and any extra medication that you take;

Take the study medication that you are given at the correct time at home (under guidance);

Store the medication securely in the fridge at home; and

Not participate in any other research studies whilst you are in this study. If you have taken part in a research study (involving medication) in the last 3 months, you should make the study doctor aware of this, so we can ensure that it is safe for you to take part in this study.

Whilst you are taking part in this study we advise that you refrain from receiving vaccinations up to and including day 28, as they may interfere with the study assessments.

What is the drug that is being tested?
We will be testing a drug called SNG001. SNG001 contains the active drug Interferon-β. Interferon-β is currently used as a therapy for multiple sclerosis sufferers and is administered by injection. You will inhale the drug for this study. It has previously been given safely via inhalation to around 230 people, the majority with either asthma or chronic bronchitis.

You will be given 14 doses of SNG001 or placebo.

What are the possible disadvantages and risks of taking part?

About the drug

• There are unknown risks involved in taking part in this research.

• The risks of injected interferon-β when given via injection are well known, but the full risks of inhaling interferon-β are not known.

No safety concerns have been raised in previous studies when this drug was inhaled by asthmatics or patients with chronic bronchitis either in stable state or when they had a cold. There were no significant changes in lung function measurements, or in laboratory tests and other safety tests.

As with other medications, people treated with Interferon-β may be at risk of developing allergic reactions or anaphylaxis. Symptoms of an allergic reaction generally include overall body itching, hives (a sort of rash), skin flushing or rash. Anaphylaxis is a more serious allergic reaction that may involve dizziness, vomiting, low blood pressure and difficulty breathing. This requires prompt medical care and may be life-threatening. Administration of medications by nebuliser may cause local irritation such as cough, voice alteration, laryngitis or pharyngitis (sore throat).
In a research study like this one, every risk or side effect cannot be predicted. Each person’s reaction to a test, medication, or procedure may be different. The design of the study has taken into consideration all of the known risks; however you may have a side effect or be at risk of symptoms, illnesses and/or complications that could not be predicted by the researchers.

**About the tests**
There is a possibility that during the tests we find that you have a medical condition that you are not aware of. If this were to happen, we would notify you of this and arrange for appropriate follow up.

**What are the side effects of any treatment received when taking part?**
Avonex is the name of one of the Interferon-β drugs that is given by injection to patients with multiple sclerosis. There are side effects of a different make of Interferon-β (Avonex), when it is given as an injection. Some of the SNG001 will go through the lungs into the bloodstream, this is normal. However, the blood levels would be much lower (approximately one tenth) than those found after injection, and this will reduce the chance of some of the side effects in this list:

**Very common effects (at least 1 in 10 people are affected)**
- flu-like symptoms - headache, muscle aches, chills or a fever
- headache

**Common effects (less than 1 in 10 people are affected)**
- loss of appetite
- feeling weak and tired
- difficulty sleeping
- depression
- flushing
- runny nose
- diarrhoea (loose stools)
- feeling or being sick (nausea or vomiting)
- numbness or tingling of skin
- rash, bruising of the skin
- increased sweating, night sweats
• pain in your muscles, joints, arms, legs or neck
• muscles cramps, stiffness in the joints and muscles
• changes to blood tests. Symptoms you might notice are tiredness, repeated infection, unexplained bruising or bleeding.

Uncommon effects (less than 1 in 100 people affected)
• hair loss
• changes to your monthly period

Rare effects (less than 1 in 1,000 people affected)
• difficulty breathing

If you experience any of these symptoms or any other symptoms that you are concerned about, please report to the study team immediately by calling [add site contact details name and telephone number]

What are the possible benefits of taking part?
The potential benefits of taking part in this study is that the information that we gain from this study may lead to the advancement of a treatment for the SARS-CoV-2 infection, not just in the UK but potentially worldwide.

What happens when the research study stops?
You will continue with your normal medication when the study stops.

What happens if there is a problem?
Any complaint about the way you have been dealt with during the study or any possible harm you might suffer will be addressed. The detailed information on this is given in Part B.

Will my taking part in the study be kept confidential?
Yes. We will follow ethical and legal practice and all information about you will be handled in confidence. The details are included in Part B.

If the information in Part A has interested you and you are considering participation, please read the additional information in Part B before making any decision

PART B
What if relevant new information becomes available?
Sometimes new information becomes available about drugs. If new information becomes available about SNG001 or Interferon-β which could affect your safety or the conduct of the study, we will make you aware of this immediately. The regulatory authorities will also be informed and the study may be stopped or changed if appropriate. If the information sheet is changed, you will be asked to read the updated information sheet and sign another consent form. You will be given the opportunity to discuss this with the study team and have any questions answered. You will be able to withdraw from the study at any stage.

What will happen if I don’t want to carry on with the study?
You can withdraw from the study at any time, without giving a reason, and this would not affect either the standard of care you receive, or your legal rights. If you withdraw from the study after receiving the study medication, and it is considered to be in your best interest, the study doctor may request a follow up video call.

If you decide to withdraw, we will need to use all the data collected up to the time of your withdrawal.

What if there is a problem?
- Complaints
If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to answer your questions (covidtrialathome@soton.ac.uk). If you remain unhappy and wish to complain formally, you can do this by contacting the details below:

Jody Brookes,
Synairgen Head of Clinical Operations
Telephone: 02380512900
Email: jody.brookes@synairgen.com

Any complaint about the way you have been dealt with during the study or any possible harm you might suffer will be addressed. Please talk to one of the study team if you are concerned about any aspect of the study.

Am I covered by Insurance?
In case you have private insurance you should check with the company before agreeing to take part in the study. You will need to do this to ensure that your participation will not affect your medical insurance.

In the unlikely event that you become ill or are injured as a result of taking part in this study you will be covered by insurance held by Synairgen Research Limited. Compensation will be provided for any injury caused by taking part in this study in accordance with the guidelines of the Association of the British Pharmaceutical Industry (ABPI). We will pay compensation where the injury probably resulted from:
• A drug being tested or administered as part of the trial protocol; or
• Any test or procedure you received as part of the trial.

Any payment would be without legal commitment (please ask if you would like more information on this). We would not be bound by these guidelines to pay compensation where:
  • The injury resulted from a drug or procedure outside the trial protocol; or
  • The protocol was not followed.

In the event that something does go wrong and you are harmed during the research and this is due to someone’s negligence, then you may have grounds for a legal action for compensation against the institution responsible for such negligence but you may have to pay your legal costs. If you wish to make a claim against this insurance you should talk to your study doctor.

How will we use information about you?

Synairgen Research Limited (Synairgen) is the sponsor for this study and is based in the UK. Synairgen will need to use information from you and/or your medical records for this research project.

This information will include your initials/ NHS number/ name/ contact details/ month and year of birth. GP practice staff or delegates from Synairgen Research Ltd will use this information to do the research or to check your records to make sure that the research is being done properly.

We would also like you to provide details of an additional contact, such as a friend or family member, who we can contact if necessary.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

We will keep all information about you safe and secure.

During the study, your name, address, telephone number and/or your email address will be passed to third parties such as healthcare professionals at Synairgen Research Ltd in order to contact you to carry out the video calls; and couriers to deliver the trial materials. These parties will be bound to keeping this information confidential. The video call may be from Synairgen Research Ltd, who are developing SNG001, and who have experienced staff trained in clinical trials. The reason the company is making the video calls is because the GP practice staff might too busy to carry on with the research aspect of your care.
Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

Some of your research information may be sent to another country. They must follow our rules about keeping your information safe.

The GP practice and Synairgen Research Ltd will keep identifiable information about you from this study for 25 years after the study has finished.

When you agree to take part in a research study, the anonymised information about your health and care may be provided to researchers running other research studies in this organisation and in other organisations. These organisations may be universities, NHS organisations or companies involved in health and care research in this country or abroad. Your information will only be used by organisations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research.

**What are your choices about how your information is used?**

You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.

We need to manage your records in specific ways for the research to be reliable. This means that we won’t be able to let you see or change the data we hold about you.

**Where can you find out more about how your information is used?**

You can find out more about how we use your information at [www.hra.nhs.uk/information-about-patients/](http://www.hra.nhs.uk/information-about-patients/), our leaflet available from [www.hra.nhs.uk/patientdataandresearch](http://www.hra.nhs.uk/patientdataandresearch), by asking one of the research team, by sending an email to john.ward@synairgen.com or by ringing us on 02380 512800.

**Involvement of the General Practitioner/Family doctor**

If you are not recruited by your own GP, they will be informed about your participation in the study with your consent. Your GP is contacted as a safety precaution, and it is in your best interests if you go to your GP with a medical problem during or shortly after the study period. We may also ask your GP for confirmation of your medical history. It is important for the study doctor to know about your medical history so that you are not put at unnecessary risk. We may also ask your local pharmacy or local clinic (if you attend one) for more information about your medical history.
Information from hospital admissions
If you are admitted into hospital during your time on the trial, we may ask the hospital team treating you to contact us with information about your hospital stay. The hospital team may provide us with information about your condition and any treatment that you are given whilst in hospital. This information will help us answer the research questions and ensure that there are no safety concerns with the trial treatment.

What will happen to the results of the research study?
The results of the research will be evaluated to help understand how SNG001 may prevent and treat patients infected with SARS-CoV-2. The results and findings may be published in scientific papers and presented at meetings. Your identity will not be disclosed in any of these. If you wish, we can notify you if an article based on the results of this study is published.

The findings may become the subject of commercial research and development by Synairgen or other companies. You will not be able to derive any personal financial benefit from this study. This means that you have no claim to any revenue received by any academic institution or commercial entity as a result of their use of the samples or data. This includes revenue received as a result of any inventions or discoveries made as a result of this research.

Who is organising and funding the research?
This study is sponsored and organised by Synairgen Research Ltd, a company specialising in asthma and COPD research. The Chief Investigator is Prof. Tom Wilkinson. He is a consultant to the company. The research nurses and doctors working on the study may be employees of Synairgen. They may also own shares or share options in Synairgen.

Who has reviewed the study?
This study has been reviewed by expert respiratory doctors who are also currently fully involved both at local and government level in the SARS-CoV-2 discussions. In addition, this research has been looked at by an independent group called a Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This study was given a favourable ethical opinion for conduct by the North West Haydock Research Ethics Committee. The government agency called the Medicines and Healthcare products Regulatory Agency (MHRA) have also given approval for this study to proceed.
Further information and contact details
If you require further information about being in a clinical study, the following link may assist you. It provides information about how clinical trials are run and what to expect if you take part in a trial.

http://www.nhs.uk/conditions/Clinical-trials/Pages/Introduction.aspx

If you would like to know more about this study, you can contact the study team who will explain more about the study and discuss any questions that you have.

Study team contact details: covidtrialathome@soton.ac.uk

If you would like advice about whether you should participate in the study, you may want to contact your GP surgery or the study team. It is often useful to discuss the study with your friends and family.

If you are unhappy with any treatment you receive during the study and would like to discuss it with someone who is not in the study team, you can contact:

Jody Brookes,
Synairgen Head of Clinical Operations
Telephone: 02380512900
Email: jody.brookes@synairgen.com

Thank you once again for reading this information sheet, and for considering participation in the research.
INFORMED CONSENT FORM

Treatment for patients with confirmed SARS-CoV-2 infection

A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

PART A

PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH STATEMENT:

1. I agree to take part in research study SG016.

2. I confirm that I have read and understood this participant information sheet and informed consent form dated 22 Feb 2021. I have had the opportunity to consider the information, ask questions and have had these questions addressed satisfactorily.

3. I understand that agreeing to take part in the research study means that I am willing to undertake all of the assessments described in this participant information sheet and also, take the trial medication.

4. I understand why the research is being done. I am aware that there are unknown risks in taking the trial medication and those risks that are known have been explained to me.

5. I understand that my participation in this study is voluntary and that I am free to withdraw at any time without giving any reason and without my medical care or legal rights being affected.

6. I understand that sections of any of my medical notes may be looked at by individuals or representatives from Synairgen Research Ltd ("Synairgen") or delegates, staff working at the GP practice, or regulatory authorities, where it is relevant to my taking part in this study. I give permission for these individuals to have access to my records.

7. I have read the above information about the data being collected in the study and my rights under the law.

8. I agree to my primary care doctor being informed of my participation in this study and to my primary care doctor being approached for my medical history if necessary.
9. If I am admitted to hospital during the trial, I agree to the trial team contacting the hospital team responsible for my care in order to collect information about my admission.

10. I understand that my primary care doctor and I will be informed if any of the results of the medical tests done as part of the research are important for my health. However, I also understand that the research may not directly benefit my health.

11. I understand that I will not benefit financially, or have any commercial rights to products that may be developed based on research on my samples, including the development of SNG001.

12. I hereby explicitly consent to the recording of my personal data during the study and the transmission of such data to Synairgen, its affiliated companies and retained service providers and the competent medicinal product authorities (the ‘Authorities’) in each country the research is being conducted. I agree that representatives of Synairgen and the Authorities (in either case both within or outside the EU) may review and process my personal data and use the same for the conduct and monitoring of the clinical trial, drug safety, registration and other lawful purposes.

13. I understand that no information that could lead to my identification will be disclosed in any reports on the project. No identifiable personal data will be published.

14. I confirm that I am not currently involved and have not been involved in any research studies involving biologicals in the past 3 months or small molecules in the past 30 days and it has been confirmed that it is safe for me to participate in another trial or studies.

15. I confirm that I give my permission for my name, address, telephone number and email (only if required) to be provided to the study team and others working on the study including Synairgen employees in order to contact me by telephone, video call and/or email on a daily basis throughout the study. I give permission for my name and address to be passed onto the trial couriers to deliver study materials.

_________________________  ___________________________  ________________
Name of Patient            Signature                      Date and Time

Name of Person witnessing consent

_________________________  ___________________________  ________________
Name of Person            Signature                      Date and Time

Name of Investigator

_________________________  ___________________________  ________________
Name of Investigator      Signature                      Date and Time